Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.

Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.

The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.

Rare kidney trials miss enrollment timelines for the same reason most clinical projects fail: eligible patients reach sites too slowly and in insufficient numbers.

RoosterBio has partnered with MineBio Life Sciences to expand access to scalable, research-grade and cGMP-grade MSC solutions across China.

Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for Hypercon technology.

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash.

Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled ...

Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HCRx to support the planned launch of AD109.

Otsuka Pharmaceutical is to fully acquire Transcend Therapeutics via its subsidiary Otsuka America for a potential ...

In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.